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Abstract
Peroxisome proliferator-activated receptors (PPARs) belong to a ligand-dependent nuclear receptor family. In 
the past decade, numerous studies have revealed the presence and significance of PPARs in the reproductive 
system. PPARs are expressed at different levels of hypothalamic-pituitary-gonadal (HPG) axis. They are also 
present in the uterus as well as in the placenta and embryonic tissues of different species. PPARs significance 
has been reported during the estrous/menstrual cycle and pregnancy with the gamma isoform studied most 
frequently. Several studies indicate that PPARs regulate proliferation of ovarian cells, tissue remodeling and 
steroidogenesis. In the endometrium, PPARs are engaged in the regulation of prostaglandins, steroids and 
cytokines synthesis. The role of PPARs in the trophoblast differentiation, maturation and invasion as well as in 
the embryo development has also been demonstrated. In this review, we summarize current findings concerning 
the role of PPARs in the regulation of reproductive functions at different levels of the HPG axis during various 
physiological statuses of females. In addition, the role of PPARs in the modulation of uterine functions as well 
as the placenta and embryo development has also been discussed. (Folia Histochemica et Cytobiologica 2015, 
Vol. 53, No. 3, 189–200)
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Abbreviations: 3b-HSD — 3-b-hydroxysteroid dehy-
drogenase/D-5-4 isomerase, CL — corpus luteum, 
CYP — cytochrome P450, E2 — estradiol, FSH — 
follicle-stimulating hormone, HP axis — hypotha-
lamic-pituitary axis, IL — interleukin, LH — lutein-
izing hormone, MMP — matrix metalloproteinase, 
NOS — nitric oxide synthase, P4 — progesterone, 
PCOS — polycystic ovary syndrome, PG — prosta-
glandin, PPAR — peroxisome proliferator-activated 
receptor, StAR — steroidogenic acute regulatory 
protein, TNFa— tumor necrosis factor alpha, TZD 
— thiazolidinediones, VEGF — vascular endothelial 
growth factor
Introduction
Peroxisome proliferator-activated receptors (PPARs) 
are members of the nuclear receptor family which 
belong to the steroid receptor superfamily. To date, 
three subtypes of these receptors, encoded by dis-
tinct genes, have been described as PPARa, PPARb 
(named also PPARd) and PPARg [1–3]. Moreover, 
three variants of PPARg, created by alternative pro-
moter usage and splicing, have been characterized as 
g1, g2 and g3 [4].
PPARs create a structure typical for nuclear recep-
tors and their activation requires heterodimerization 
with another nuclear receptor, 9-cis retinoic acid re-
ceptor (RXR). The heterodimer binds afterwards to 
a specific DNA sequence — peroxisome proliferator 
response element (PPRE), and activates transcription 
of various target genes. PPARs are modulated by 
numerous cofactors that enhance (as co-activators) 
or reduce (as co-inhibitors) their activity [5].
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PPARs are ligand-dependent structures that are 
activated by natural and synthetic compounds. PPARs 
can also be activated in the absence of the ligand or 
by alternative pathways like the phosphorylation. 
Natural activators comprise unsaturated fatty acids, 
eicosanoids, prostaglandin (PG)-related compounds 
or oxidized lipids while a large group of synthetic lig-
ands includes hypolipidemic drugs (fibrates), anti-in-
flammatory (e.g. indomethacin and fenoprofen) or 
insulin-sensitizing drugs (thiazolidinediones, TZDs) 
[6]. Moreover, a treatment with TZDs improves fer-
tility through an induction of ovulation in women with 
polycystic ovary syndrome (PCOS) [8]. 
The presence of all PPAR isoforms has been found 
in various female reproductive tissues in different 
species. Experiments with knockout rodents suggest 
the role of PPARs in the regulation of reproductive 
functions. An inactivation of PPARg indicated serious 
consequences that lead to the death of mouse embryo 
at an early stage of development [9]. PPARb-null 
mice showed abnormalities in placenta development 
that increased embryos mortality [10]. The adminis-
tration of the specific PPARb agonist reversed the 
implantation disorders in rats and it even increased 
the number of implanted embryos compared with the 
control group [11]. Rodents lacking PPARa displayed 
a higher risk of maternal abortion and neonatal mor-
tality [12]. In this review we attempt to summarize 
present knowledge and discuss the results on the role 
of PPARs in the regulation of reproductive functions 
in females.
PPARs and the hypothalamic- 
-pituitary (HP) axis
The expression of PPAR isoforms has been detected 
in mouse, ovine and human pituitary gland [13, 14] 
and in rodent hypothalamus [15], but their signif-
icance in the regulation of reproductive functions 
at the level of hypothalamic-pituitary (HP) remains 
poorly understood. It has been demonstrated that 
PPARg activation by TZDs inhibited the development 
of pituitary adenomas in mice and humans [18, 19] 
but did not affect the secretion of prolactin (PRL), 
follicle-stimulating hormone (FSH) or luteinizing 
hormone (LH) by ovine pituitary or LH by murine 
LbetaT2 gonadotrophic pituitary tumor cell line 
[16]. However, recent data indicate a direct role for 
PPARg in the modulation of pituitary function [18]. 
Rosiglitazone suppressed GnRH-mediated induction 
of LH and FSH genes expression and a conditional 
knockout of PPARg in pituitary gonadotrophs caused 
an increase in LH levels in female mice and reduced 
litter size [18]. The presented above data suggest the 
involvement of PPARs in the regulation of reproduc-
tive processes at the HP axis but this knowledge is too 
narrow to define its specific role. 
PPARs in the ovary
All PPAR isoforms are expressed in ovaries of differ-
ent species including rodent, sheep, cow, pig, rabbit, 
buffalo and human [14, 19–21] but the role of gamma 
isoform has been studied most extensively compared 
with two other forms. Many studies have shown 
that PPARs gene and/or protein expression varies 
depending on ovarian cell type, physiological status 
and the species [14, 22–26]. It has also been frequently 
reported that PPARs are engaged in the regulation of 
various ovarian functions. A tissue-specific deletion 
of PPARg in mouse ovary markedly reduced fertility 
[19]. Although these mice had a normal number of fol-
licles and developed corpora lutea, progesterone (P4) 
level was reduced, implantation rates were lower and 
litters were smaller [19]. An administration of PPARg 
agonist for 4 weeks did not affect folliculogenesis, but 
increased plasma P4 concentration [27]. There is a lack 
of similar studies on the tissue-specific deletion of the 
two remaining PPAR isoforms. 
PPARs and remodeling of the ovarian tissue 
It has been demonstrated that PPARg modulates 
follicular development, oocyte maturation, ovulation 
and the CL formation or regression [22, 28]. These 
effects are mediated by the regulation of several genes 
controlling angiogenesis, inflammatory response, 
apoptosis and cell cycle. It was suggested that PPARg 
may be involved in ovulation and luteinization by in-
hibiting the secretion of pro-inflammatory cytokines 
such as tumor necrosis factor (TNF) a and interleu-
kin (IL)-6 in human granulosa-lutein cells [29]. In 
ovarian macrophages, inducible nitric oxide synthase 
(NOS2), an important pro-inflammatory enzyme that 
regulates ovulation, was also reduced after treatment 
with PPARg agonist [30]. 
There is evidence that PPARg activation affected 
the proliferation of ovine granulosa cells but showed 
no impact on the apoptotic markers [14]. In turn, in 
rodent luteal and granulosa cells vitality was modu-
lated by the regulation of anti-apoptotic bcl-2 protein 
and tumor suppressor p53 expression [31, 32]. PPARs 
may affect the expression and activity of proteases 
and angiogenic factors which are engaged in the 
tissue remodeling and the formation of follicular or 
luteal cells. Although the interaction between PPARs 
and matrix metalloproteinases (MMP-3, -9, -13), 
plasminogen activators, vascular endothelial growth 
factor (VEGF) and its receptors (Flt-1, Flt-2) as well 
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as angiopoietin-like protein 4 (ANGPTL4) has been 
noted in various tissues including tumors [22, 33], the 
existence of such association in ovarian tissue needs 
confirmation. 
PPARs and steroidogenesis
PPARs appear to be important regulators of steroid 
(P4 and E2) production. It has been frequently report-
ed that activators of PPARg regulate steroidogenesis 
in follicular cells of different species but the available 
results are contradictory. Stimulatory effect of syn-
thetic or natural activators of PPARg on P4 secretion 
was noted in mixed culture of human stromal, theca 
and granulosa cells [34], rat granulosa cells [35], ovine 
granulosa cells [14], porcine theca cells [20] and por-
cine follicles [36]. In turn, a lack of changes in P4 or E2 
production was observed in human granulosa-lutein 
cells [29]. There are also studies showing an inhibi-
tory effect of PPARg activators on P4 production by 
cultured porcine and human LH-stimulated granulosa 
cells [37, 38]. Recent data showed that the activation 
of PPARa and PPARg affected steroidogenesis and 
follicle development in mouse preantral follicles treat-
ed with tumor necrosis factor alpha (TNFa), used as 
a model for studying follicle development in patients 
with PCOS [39]. Moreover, polymorphism in PPARg 
gene is associated with metabolic disorders and abnor-
mal blood E2 concentration in PCOS patients [40, 41].
There is a limited amount of studies showing the 
effect of PPARs activation on steroidogenesis in lu-
teal cells. PPARg agonists enhanced P4 production in 
bovine luteal cells collected during mid-luteal phase 
of the estrous cycle [42] or by corpora lutea explants 
of pseudopregnant rabbits [21]. However, there was 
no effect of PPARg ligands on P4 production in he-
misected and cultured rat CL [32]. Our recent results 
indicate that PPAR (a, b, g) activators reduced P4 
secretion by the CL explants during early stages (days 
10–12 and 14–16) of pregnancy, whereas they were in-
effective during the corresponding days of the estrous 
cycle [43]. Moreover, PPARa agonist diminished E2 
secretion by the CL explants collected during mid- 
and late-luteal phases of the estrous cycle and early 
pregnancy while natural or synthetic PPARg ligands 
did not affect E2 release. In turn, PPARb activation 
inhibited E2 release by the CL during early pregnancy, 
but did not affect the secretion during luteal phase of 
the estrous cycle [43]. The effect of PPAR ligands on 
steroidogenesis can be mediated by a modulation of 
steroidogenic enzymes action. However, inconsistency 
in their expression and activity has been often demon-
strated by researchers. For instance, a stimulatory 
effect of PPARg activation on steroidogenesis can 
be mediated by up-regulation of steroidogenic acute 
regulatory (StAR) protein in human and macaque 
granulosa cells [44, 45] or by 3b-HSD in porcine ovar-
ian follicles [36]. An opposite effect of PPARg ligands 
on 3b-HSD expression and P4 release was observed 
in porcine granulosa cells [37]. There are also studies 
showing that PPARg or PPARa activation inhibited 
aromatase expression in human granulosa cells and 
mouse ovary [46, 47]. Different studies, including ours, 
indicate that changes in steroids production evoked by 
PPAR ligands are not always followed by alternations 
in genes or proteins expression of 3b-HSD in porcine 
endometrium and ovine granulosa cells [14, 43], 
CYP11A1 in ovine granulosa cells [14] or CYP17 in 
porcine theca cells [20]. The discrepancies in steroids 
production or expression of enzymes responsible for 
steroids synthesis could be a result of differences in 
species, ovarian cells type, physiological status, type 
and dose of PPAR ligands, time of the tissue incuba-
tion with the treatments. 
The above results revealed that PPARs are en-
gaged in the regulation of various ovarian functions 
in different species. They also suggest a different 
receptivity of the tissue to PPAR agonists depending 
on physiological status of individuals. However, mo-
lecular mechanisms of PPARs, especially alpha and 
beta isoforms, action in the ovary still remains not 
fully understood. Because certain PPAR ligands are 
clinically used to treat diabetes or polycystic ovary 
syndrome (PCOS), the understanding of their exact 
role in the ovary should be an important reason of 
interest. 
PPARs in the uterus
Compared to the research on PPARs in the ovary, the 
studies on their functions in the uterus are limited. 
Most experiments were carried out in the endome - 
trium, where several essential events occur intended 
for preparation of the tissue to the embryo implan-
tation, placentation and pregnancy sustain. The 
expression of all PPAR isoforms has been demon-
strated in human, bovine, ovine, porcine and rodent 
endometrial tissue [48–50]. 
Previously published data indicate that PPARa 
and PPARb expression markedly increased in rodent 
endometrial stroma at the beginning of implan-
tation [50] while PPARg mRNA level was higher 
during fertilization but declined at the beginning 
of implantation [50]. In the endometrium of preg-
nant cows, a lack of differences in PPARg mRNA 
level was noted [51], while in ovine endometrium 
the expression of PPARb stayed at a constant level 
on days 7–17 (peri-implantation period), PPARg 
declined from days 7 to 17 and PPARg peaked 
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first at day 9 and then on day 17 [49]. Differences 
in PPARb and PPARg gene expression were also 
reported in porcine endometrium [52]. A higher 
expression of PPARb was reported on day 15 of the 
estrous cycle (during luteolysis) compared with days 
15 and 25 of pregnancy (peri-implantation period). 
In turn, the transcript level of PPARg was elevated 
during the tested days of pregnancy compared with the 
level on day 15 of the estrous cycle [52]. The results 
of our studies [26] showed increased mRNA levels of 
PPARa and PPARb during the luteal phase compared 
with the follicular phase of the estrous cycle. During 
pregnancy, the decreased PPARa and PPARb mRNA 
levels were noted on days 11–12 (the time of maternal 
recognition of pregnancy) and higher on days 13–15, 
at the beginning of implantation. In turn, the PPARg 
gene expression was higher on days 13–15 of the es-
trous cycle (during luteolysis) than on the remaining 
days while during pregnancy the transcript level was 
increased on days 16–30 of pregnancy (peri-implanta-
tion period) compared with days 5–15 [26]. In another 
experiment performed on gilts subjected to surgical 
procedures, we reported markedly increased mRNA 
levels of PPARa and PPARb, but not PPARg, in the 
endometrium collected from the uterine horn with 
fetuses on day 14 of pregnancy compared to the horn 
without embryos [53]. 
The above results have shown that uteri of dif-
ferent mammal species express all PPAR isoforms. 
The discrepancy in their expression pattern, which 
was often reported, can be related to physiological 
status of individuals or species. Differential PPARs 
expression profile during various reproductive con-
ditions suggest their involvement in the regulation 
of uterine secretory function which can be crucial 
for luteolysis of the CL during the estrous cycle or 
the embryo implantation during pregnancy. PPARs 
effect at the endometrial level can be mediated by 
a number of ways. 
Interactions between PPARs  
and prostaglandins (PGs)
The endometrial tissue is a place where PPARs can 
regulate the expression and activity of prostaglandin 
endoperoxidase synthase 2 (PTGS2, COX-2, PTGH) 
— a rate-limiting enzyme responsible for PGs synthe-
sis. Endometrial PTGS-derived PGF2a and PGE2 are 
crucial in the regulation of the CL activity through 
respective luteolytic or luteotrophic actions in various 
species [54, 55]. PGs significance has been highlight-
ed in the regulation of ovulation, the CL functions, 
maternal recognition of pregnancy, implantation and 
parturition [56]. Recently, the role of PTGS-derived 
PGI2 (prostacyclin) has been reported in the regu-
lation of blastocyst development, embryo hatching 
and the implantation course in mice and pigs [57, 58]. 
It has been suggested that there is a direct in-
teraction between PGs and PPARs, because PPAR 
response element was identified in the PTGS2 gene 
promoter [59] and the activation of PPARs affected 
PTGS2 expression in various cell or tissue types in-
cluding human [60] and bovine endometrial cells [48, 
61], WISH cells line and primary amnion cells [62]. 
The administration of different PPARb agonists to the 
PTGS2 deficient mice restored reduced implantation 
rates what indicates a direct interaction between these 
pathways [63]. In addition, the treatment of bovine 
endometrial cells with PPARa and PPARb activators 
enhanced both PGE2 and PGF2a production [48]. Our 
studies showed that PPARa, PPARb and PPARg 
agonists stimulated PGF2a secretion by porcine en-
dometrium during mid- and late-luteal phase of the 
estrous cycle whereas the ligands were less effective 
during the corresponding days of pregnancy. In addi-
tion, the tested PPAR agonists did not affect PGFS 
gene expression during luteal phase of the estrous 
cycle, but they modulated the enzyme mRNA level 
during peri-implantation [64]. This suggests different 
sensitivity of porcine endometrium to PPAR ligands 
associated with the physiological status of animals. 
We have recently reported that PPARs are me-
diators of PGE2 production in the porcine endome-
trium during the luteal phase of the estrous cycle and 
the time of peri-implantation. Ligands of PPARg or 
PPARb enhanced both the synthesis and accumula-
tion of PGE2 in culture media depending on the phase 
of the estrous cycle or pregnancy, whereas PPARα 
ligands were less effective in PGE2 production [65].
As mentioned before, PPARs can interact with 
PGI2 and certain PGI2 analogues can act as ligands 
for the PPARb. This ability suggests that the effects 
of PGI2 may be mediated by PPARb in mouse, rat 
and sheep uterus [49, 66, 67]. An interaction between 
PGI2 and PPARb facilitated implantation in mouse 
by increasing the number of implanted embryos [63]. 
It has been recently reported that PGI2-induced 
PPARb activation accelerated blastocyst hatching in 
mice [57] and a deletion of PPARb at early stages of 
preimplantation of mouse embryos caused a delay of 
blastocyst hatching. 
Interactions between PPARs and steroids 
Apparently, steroids (P4 and E2) are crucial regulators 
of architectonical alterations in the uterine structures. 
They regulate cell proliferation, differentiation and 
remodeling of various uterine cell types depending 
on the female physiological status [68]. The CL is the 
main source of steroid hormones in the uterine tissue, 
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although steroidogenic activity of the endometrium 
has been also reported [69]. There are available data 
documenting a possible interaction between steroids 
and PPARs in the uterus. PPARg activation increased 
mouse uterine mass, proliferation and evoked mor-
phogenetic alterations in the tissue [70]. PPARs can 
bind to the estrogen response element (ERE) in 
targeted genes and act as a regulator of the estrogen 
receptor (ER) expression [71]. There is evidence that 
PPARa or PPARg activation affected the protein 
level of ERg in all mouse uterine compartments 
[70]. It has been suggested that PPARg activation 
increases proliferative estrogen action and facilitates 
estrogen-dependent endometrial hyperplasia but 
PPARa activation has an opposite effect — attenu-
ates estradiol impact on the uterus by reducing cell 
proliferative capacity [70].
PPARs can also be engaged in steroids synthesis 
in the endometrial tissue. Our unpublished results 
suggest that the receptors can mediate P4 and E2 pro-
duction in porcine endometrial explants depending on 
the physiological status of animals. For instance, an 
inhibitory effect of PPAR (a, b, g isoforms) agonists 
on P4 release was noted during mid-luteal phase of the 
estrous cycle but not in late-luteal phase. In addition, 
PPARa and PPARg agonists reduced E2 secretion 
during early pregnancy while PPARb and PPARg 
activation increased the secretion during luteal phase 
of the estrous cycle. 
Interactions between PPARs and cytokines
It has been frequently reported, that cytokines, me-
diators of immune response, are important regulators 
of reproductive functions. Their significance has been 
described during the estrous/menstrual cycle, but 
majority of the studies focused on their role during 
implantation, when the regulation of maternal im-
mune response to an antigenically different embryo 
is required. The endometrium secretes a number of 
cytokines such as IL-1, IL-6, leukemia inhibitory fac-
tor (LIF), colony stimulating factor 1 (CSF-1), TNFa 
[72]. They are engaged in the preparation of endo-
metrium for the embryo implantation, PGs synthesis, 
trophoblast elongation, placenta development and 
pregnancy maintenance [69, 73]. Uterine disorders 
such as inflammation, adenomyosis, endometriosis 
are accompanied by altered number of cells synthetiz-
ing cytokines and an unbalanced amount of secreted 
cytokines [74, 75].
Interactions between PPARs and cytokines have 
been frequently suggested though most researchers 
described PPARs as significant immunomodulators in 
non-reproductive cells or tissues [76]. Only two groups 
of researchers reported that PPARg ligands modulat-
ed the secretion of IL-1, IL-6, IL-8 or colony stimu-
lating factor-1 (CSF-1) by human endometrial cells 
[77, 78]. Contrary, a modulatory effect of cytokines 
on PPARs activity has also been reported. The results 
of our studies indicate that IL-6 and interferon g 
(IFNg) had an impact on PPARs gene expression in 
the porcine endometrium on day 14 of the estrous 
cycle or pregnancy [79]. We demonstrated a very weak 
effect of the cytokines during the estrous cycle, but 
a strong effect during pregnancy. IFNg affected the 
expression of all PPAR isoforms while IL-6 influenced 
only PPARg gene expression [79]. 
There are some reports suggesting that PPARg 
plays an important role in the regulation of inflamma-
tory processes in the endometrium [80] and the inhibi-
tion of the immune response expressed by a decreased 
synthesis of IL-6 and IL-8 could be effectively used to 
treat endometriosis in women [78]. Further research 
is required to find out whether PPARs are involved 
in the regulation the synthesis of cytokines — factors 
that modulate mother’s immune response during early 
pregnancy (physiological state) and if they are an im-
portant link in the course of inflammatory processes 
in the female reproductive system (pathological state). 
PPARs in the placenta
Human and animal studies have shown that PPARs 
play a regulatory role in placental development and 
functions [81–83]. Three isoforms of PPARs have 
been detected in placentas of a limited number of 
species including mouse, rat, ovine and human [49, 
84, 85]. Recently, PPARg expression has been also 
confirmed in bovine throphoblast [86]. Depending 
on the species and pregnancy stage, PPARs display 
a different expression in diverse compartments of the 
placenta [82, 87, 88]. 
It has been frequently reported that the principal 
role in human and rodent placenta development is 
played by PPARg. In rodents, the role of PPARg in 
trophoblast differentiation, maturation and invasion 
seems to be established. PPARg expression in rat 
placenta was high on day 13, during placental dif-
ferentiation and maturation, and later significantly 
declined [85]. In addition, oral administration of 
PPARg ligand enhanced PPARg transcript level in 
the rat placenta and decreased embryos mortality by 
half [85]. Mice lacking this isoform (PPARg–/–) die on 
day 10 of gestation due to the defects in trophoblast 
differentiation, placental vascularization and nutri-
tional transport to the developing embryos [89]. Re-
cent reports indicate that in fully viable PPARg-null 
mice, obtained through specific and total epiblastic 
gene deletion, the placental vasculature defects, which 
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are associated with unbalanced expression of pro- and 
antiangiogenic factors, might be a major reason of 
embryonic lethality [90]. In the same study the authors 
indicated that PPARg activation affected mouse pla-
cental microvasculature and the layers organization 
by the regulation of proangiogenic genes expression 
such as proliferin (PLF), vascular endothelial growth 
factor (VEGF) and platelet-endothelial cell adhesion 
molecule-1 (Pecam1) [90]. PPARg affects rodent 
trophoblast differentiation by interaction with various 
coactivators such as PPAR-binding protein (PBP) and 
PPAR-interacting protein (PRIP) [91]. In addition, 
the important role of PPARg in placental develop-
ment depends on the expression of anti-adhesive 
molecule Muc1, which is expressed in placenta, but 
not in other tissues such as adipocytes [92]. 
In humans, the role of PPARg in placental de-
velopment is less clear and the results of mainly in 
vitro experiments have not been always consistent. 
Available data indicate that PPARg activation mod-
ulates the differentiation of cytotrophoblast into 
syncytiotrophoblast [93]. It has been also suggested 
that PPARg-dependent trophoblast differentiation 
process is mediated by the increase of chorionic gon-
adotropin beta-subunit (hCGb, biochemical marker 
of trophoblast differentiation) expression and secre-
tion as well as by the synthesis of human placental 
lactogen (hPL), human placental growth hormone 
(hPGH) and leptin [93]. Interestingly, whereas the 
exposure of cultured primary trophoblasts to synthetic 
PPARg ligand enhanced trophoblast differentiation, 
the natural ligand had opposite effect and promoted 
trophoblast apoptosis through p53 up-regulation [94].
PPARg plays an important role in the trophoblast 
invasion. Tarrade et al. [95] reported that PPARg is 
highly expressed in human cytotrophoblasts at the 
feto-maternal interface, particularly in the extravil-
lous cytotrophoblasts involved in uterus invasion. 
They also showed that both synthetic and natural 
PPARg agonists inhibited extravillous cytotrophoblast 
invasion and the treatment with PPARg antagonist 
facilitated the invasion process [95]. Recently, the 
analysis of PPARg-target genes in human trophoblast 
led to characterization of new factors engaged in the 
regulation of trophoblast invasion [82, 83, 96]. Among 
those, heme-oxygenase-1 (HO-1), human placental 
growth hormone (hPGH), the pregnancy-associated 
plasma protein (PAPP-A) and hCG seems to have 
a significant role in this process [97–99]. Moreover, 
the role of PPARs in the immune response and im-
munotolerance during trophoblast invasion cannot 
be neglected [100]. Indeed, there is evidence showing 
PPARg-dependent inhibition of the production of 
cytokines such as IL-1b, IL-6, IL-8, IL-10 and TNFa in 
human placenta as well as in amnion and choriodecid-
ua [101]. An important relationship between cytokines 
and PPARs can be suggested during the beginning of 
parturition when an increased production of pro-in-
flammatory cytokines [102] correlates with changes 
in PPARs expression in human placental tissues [88]. 
One should also not disregard the importance of 
PPARg in the regulation of placental lipid homeo-
stasis even if available data are limited. Transfer of 
fatty acids from the mother to the fetus is absolutely 
necessary for a proper embryo development, im-
plantation, placenta development, and pregnancy 
maintenance [103, 104]. Various proteins engaged in 
fatty acid binding, transport, b-oxidation and lipid ac-
cumulation are expressed in the placental tissue [105]. 
It has been suggested that the absence of PPARg or 
PPARb might lead to the defects of placenta and 
fetus development due to an impaired placental/fetal 
fatty acid homeostasis [10]. The activation of PPARg 
regulates fatty acid uptake and lipid storage in primary 
human trophoblasts. This effect was characterized by 
an increased expression of genes encoding fatty acid 
transporters (FATP1 and FATP2) and a fat droplet 
associated protein, adipophilin [81, 106]. There are 
also reports suggesting a possible role of PPARs in 
the regulation of proteins involved in placental fatty 
acid/lipids metabolism such as cytochrome P450 
4A (CYP4A), cyclooxygenases and lipooxygenases 
(LOX) [105]. 
Although the role of PPARg in placental devel-
opment is significant and unquestionable, there is 
evidence that PPARb can also be an important player 
in this process. As mentioned before, a lack of PPARα 
in the rodent model resulted in severe placenta defects 
caused mainly by the loss of connection between the 
placenta and decidua [10]. In comparison to wild-type 
animals PPARb–/– pregnant mice exhibited smaller 
placental labyrinth, maternal bleeding to the labyrinth 
and increased fetal mortality [10]. PPARb is involved 
in trophoblast growth by regulating differentiation of 
trophoblast giant cells via PI3K/Akt pathway that is 
important in the blastocyst implantation, alteration 
of the maternal decidua structure and secretion of 
hormones such as placental lactogens I and II (PL-I, 
PL-II) and proliferin [107]. 
While the role of PPARg in trophoblast differen-
tiation, invasion and placental functions have been 
extensively studied in human and rodent models, the 
involvement of other PPAR isoforms has not been not 
fully explained. In addition, most studies have only 
been performed in humans and rodents having inva-
sive placentas. Therefore, it is reasonable to conduct 
similar studies in mammals with non-invasive placentas, 
occurring in domestic animals such as pigs, cows and 
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mares. Moreover, further studies are also required for 
a better understanding of the role of PPARs in the 
regulation of fatty acid homeostasis, angiogenesis and 
inflammatory responses during pregnancy.
PPARs in the embryo
The expression of all PPARs has been found in bo-
vine, human and mouse embryos [108, 109]. PPARb 





Gonadotrophins (LH and FSH) 
synthesis
Ovary 
Steroids (P4 and E2) synthesis
– –
Ovulation and luteinisation through 
the regulation of TNFa and IL-6 
Tissue remodeling through the 
regulation of MMP-9
–
Tissue remodeling through  
the regulation of MMP-3, -9, -13, 
plasminogen activators 
– –
Angiogenesis through the regulation 
of VEGF, its receptors (Flt-1, Flt-2) 
and ANGPTL4  
Uterus 
Steroids (P4 and E2) release
PGE2 and PGF2a synthesis
– Number of implanted embryos  
by PGI2 modulation
–
– – Cytokines (IL-1, IL-6, IL-8, CSF-1) 
release
Estrogen signalling pathway – –
Placenta
– – Trophoblast invasion by the regula-
tion of HO-1, hPGH, PAPP-A and 
hCG as well as cytokines 
(IL-1b, IL-6, IL-8, IL-10 and TNFa)
– Trophoblast differentiation by the regulation of PBP and PRIP
– – Trophoblast vascularisation by the 
regulation of Prl2c2, PLF, VEGF 
and Pecam1
– Trophoblast growth by PI3K/Akt 
pathway
–
– Fatty acid uptake and lipids storage through the regulation of fatty  
acid transporters (FATP1, FATP2) and a fat droplet associated  
protein, adipophilin 
– Fatty acid/lipids metabolism through the regulation  
of CYP4A, COX and LOX
Embryo 
– Embryo implantation by the effect on fatty acid metabolism
Long-term foetal adaptations to 
the maternal diet by epigenetic 
control of energy metabolism
Short-term foetal adaptations to the maternal diet by the control  
of cell growth and differentiation
– – Neurons differentiation
– Prevents neuronal death –
‘–‘ — lack of data concerning PPARs effect on reproductive tissues; COX — cyclooxygenases; CSF-1 — colony stimulating factor 1; CYP4A —  
cytochrome P450 4A; E2 — estradiol; FATP — fatty acid transporters; Flt — fms-related tyrosine kinase; angiopoietin-like 4 protein; FSH — 
follicle-stimulating hormone; hCG — human chorionic gonadotropin; HO-1 — heme-oxygenase-1; hPGH — human placental growth hormone; 
IL — interleukin; LH — luteinizing hormone; LOX — lipooxygenases; MMP — matrix metalloproteinase; P4 — progesterone; PAPP-A — the 
pregnancy-associated plasma protein; PBP — PPAR-binding protein; Pecam1 — platelet/endothelial cell adhesion molecule 1; PGE2 — prosta-
glandin E2; PGF2a — prostaglandin F2a; PGI2 — prostaglandin I2/prostacyclin; PI3K/Akt — phosphatidylinositol-3 kinase/RAC-alpha serine/thre-
onine-protein kinase; PLF — proliferin; PRIP — PPAR-interacting protein; Prl2c2 — prolactin family 2, subfamily c, member 2; TNFa — tumor 
necrosis factor a; VEGF — vascular endothelial growth factor
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and PPARg facilitate the embryo implantation and 
placenta development through the effect on lipids, 
carbohydrates and amino-acids metabolism. Produced 
metabolites can be used by the fetus as substrates for 
energy metabolism, synthesis of the membranes and 
signaling molecules [110]. Interestingly, the fetal adap-
tations to the maternal diet might be regulated by two 
mechanisms. The first, short-term, mediated by PPARb 
and PPARg regulates cell growth and differentiation, 
while the second one, long-term, mediated by PPARa 
seems to be related to the epigenetic control of energy 
metabolism to optimize postnatal survival [110]. 
PPARa was also described as an important regu-
lator of lipid catabolism in fetal liver and heart [111, 
112]. An additional role of PPARs has been revealed 
during the development of embryonic nervous sys-
tem. An activation of PPARg by natural agonists 
promoted neuronal differentiation in 17-day-old rat 
fetuses [113]. In addition, PPARb agonist prevented 
inflammation-induced neuronal death in micro-
glia-neuron in in vitro co-cultures [114]. Based on the 
above results, it seems that PPARs play a significant 
role during the embryonic development. However, it 
has to be noted that general scarcity of data should 
encourage researchers to conduct studies in this field. 
Conclusions
PPARs are expressed at different levels of hypothala-
mic-pituitary-gonadal axis. They are also present in the 
uterus as well as in the placenta and embryonic tissues 
of different species. Such an extensive distribution in 
the above tissues indicates an important role of PPARs 
in the regulation of various reproductive functions 
(Table 1). Despite numerous studies concerning the 
expression and the role of PPARs in the modulation 
of female reproductive processes, several physiological 
and molecular properties of these receptors still remain 
unexplored. The understanding of the mechanisms that 
control the course of estrous/menstrual cycle, early 
pregnancy maintenance and gestation progress may 
contribute to an increase in the reproductive rates and 
improve economic parameters of farming animals. In 
addition, taking into consideration a fact, that certain 
PPAR ligands are used clinically to improve repro-
ductive disorders, a precise understanding of PPARs’ 
action in various reproductive tissues should be a sig-
nificant reason for conducting more studies. 
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